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ABSTRACT
Background
The risk of venous thrombosis is approximately 2- to 4-fold increased after air travel, but the
absolute risk is unknown. The objective of this study was to assess the absolute risk of venous
thrombosis after air travel.
Methods and Findings
We conducted a cohort study among employees of large international companies and
organisations, who were followed between 1 January 2000 and 31 December 2005. The
occurrence of symptomatic venous thrombosis was linked to exposure to air travel, as assessed
by travel records provided by the companies and organisations. A long-haul flight was defined
as a flight of at least 4 h and participants were considered exposed for a postflight period of 8
wk. A total of 8,755 employees were followed during a total follow-up time of 38,910 person-
years (PY). The total time employees were exposed to a long-haul flight was 6,872 PY. In the
follow-up period, 53 thromboses occurred, 22 of which within 8 wk of a long-haul flight,
yielding an incidence rate of 3.2/1,000 PY, as compared to 1.0/1,000 PY in individuals not
exposed to air travel (incidence rate ratio 3.2, 95% confidence interval 1.8–5.6). This rate was
equivalent to a risk of one event per 4,656 long-haul flights. The risk increased with exposure to
more flights within a short time frame and with increasing duration of flights. The incidence
was highest in the first 2 wk after travel and gradually decreased to baseline after 8 wk. The risk
was particularly high in employees under age 30 y, women who used oral contraceptives, and
individuals who were particularly short, tall, or overweight.
Conclusions
The risk of symptomatic venous thrombosis after air travel is moderately increased on
average, and rises with increasing exposure and in high-risk groups.
The Editors’ Summary of this article follows the references.
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In 1951, Jacques Louvel reported four cases of venous
thrombosis following air travel [1]. More recently, several
investigators have shown an association between air travel
and venous thrombosis, with a 2- to 4-fold increased risk in
most studies [2–8]. Two follow-up studies demonstrated a
dose–response relationship between the occurrence of
pulmonary embolism shortly after arrival at the airport and
the distance travelled [9,10]. Still, the most relevant element,
i.e., the absolute risk of symptomatic venous thrombosis after
long-distance air travel, remains unknown. One follow-up
study demonstrated an absolute risk of severe pulmonary
embolism occurring shortly after arrival of 1/200,000 pas-
sengers [9], whereas another study showed a risk of fatal
pulmonary embolism of 1.3 per million passengers [11].
Asymptomatic clots have been found in 1% to 10% of air
travellers [12–14]. Hence, the absolute risk of symptomatic
venous thrombosis after long-haul travel must lie between
these extremes.
Knowledge of the absolute risk of symptomatic thrombosis
after air travel is needed to provide travellers with solid
advice regarding their actual risk and to evaluate the utility of
prophylactic measures. Since two billion passengers ﬂy
annually (2005 data [15]), even a small increase in risk will
have a major impact on the number of events. Over-
estimation of the risk may lead to inappropriate use of
potentially dangerous antithrombotic drugs [16,17].
In addition to estimating the absolute risk of symptomatic
deep vein thrombosis or pulmonary embolism after long haul
air travel, we assessed the effects of exposure to several ﬂights
within a short time frame, duration of travel, and the
occurrence of venous thrombosis in relation to the time
passed after air travel. Finally, we determined the effect of air
travel within high-risk groups.
Methods
Study Design
We performed a cohort study among employees of large
international companies and organisations. During the
follow-up period, thrombotic events were linked to exposure
to air travel.
Participating Companies and Organisations
Participating companies and organisations were Nestle ´
(Vevey, Switzerland), General Mills (Minneapolis, Minnesota,
US), the US Centers for Disease Control and Prevention
(Atlanta, Georgia, US), the World Bank and the International
Monetary Fund (Washington, D. C., US), Shell Companies
based in The Hague (The Netherlands) and London (UK),
Shell Exploration and Production (SIEP) based in Rijswijk
(The Netherlands), Sakhalin Energy Investment Company Ltd
(SEIC) based in Sakhalin (Russia), and TNT NV (Thomas
Nationwide Transport, Hoofddorp, The Netherlands). All
organisations and companies had a central database with
records of employees’ business travel. Start of follow-up
varied per company, between 1 January 1998 and 1 January
2001 or at start of the employment if later. Follow-up ended
between 1 December 2002 and 1 January 2006, when venous
thrombosis was diagnosed or at the end of employment,
whichever occurred ﬁrst, with approximately 5 y of follow-up
per company.
Questionnaires and Flight Data
We developed Web-based questionnaires, using Apian
Survey Pro 3.0. These contained questions about venous
thrombosis occurrence (at any time point in the follow-up
period)andriskfactorsforvenousthrombosis.Employeeswere
invitedtotakepartbyapersonale-mailcontainingalinktothe
questionnaire and a uniquepassword,which ensuredthateach
individualcouldenteronlyonce.Withintervalsof a few weeks,
nonresponding employees received two or three reminders.
Thequestionnairecanbeviewedathttp://www.clinicalresearch.
nl/epidemiology/wrightquestionnaire/wrightquestionnaire.asp
(note: a password is not necessary to view the questionnaire).
Date of travel and duration of travel (not including
stopover time) were taken from the organisations’ travel
database.
Outcomes
Participants who reported venous thrombosis were asked
to ﬁll in a consent form for medical chart review. Only
symptomatic ﬁrst venous thrombotic events that were
diagnosed with objective methods were considered. Deep
vein thrombosis had to be diagnosed by compression ultra-
sonography or venography. Pulmonary embolism had to be
diagnosed by spiral CT scanning, high-probability ventila-
tion-perfusion scanning, or angiography. Superﬁcial throm-
bophlebitis was not included.
Statistical Analysis
For the analysis of the overall effect of ﬂying, exposure
time was deﬁned as a time window of 8 wk after a long-haul
ﬂight (ﬂight of at least 4 h). For each individual, the total time
exposed and not exposed was calculated. The incidence rate
(IR) of venous thrombosis within 8 wk of a long-haul ﬂight
was calculated by dividing the number of cases that occurred
in this exposure window by the number of exposed person-
years (PY). The IR of venous thrombosis without exposure was
calculated in the same way (events over person-time outside
exposure windows). The incidence rate ratio (IRR) adjusted
for age and sex was calculated using Poisson regression
analysis. The overall effect of ﬂying was assessed for the whole
group of employees and separately for subgroups based on
sex, age, oral contraceptive use, body mass index (BMI), and
height. The number of person-years exposed and unexposed
to oral contraceptive use was calculated for women younger
than 50 y.
In addition, we calculated the absolute risk of venous
thrombosis per ﬂight by dividing the number of cases that
occurred within 8 wk of a long-haul ﬂight by the total number
of ﬂights longer than 4 h made by all responding employees.
Employees were often exposed to more than one ﬂight in
the 8 wk exposure windows, so time windows were frequently
overlapping. To assess the effect of number of ﬂights, the
total time employees were exposed to one to ﬁve ﬂights or
more was calculated. Thus, IRs and IRRs for exposure to one
or two, three or four, and ﬁve or more ﬂights could be
calculated (Figure 1A). Furthermore, we calculated the
increase in risk for each extra ﬂight using Poisson regression.
To assess the effect of duration of travel, we calculated IRs
and IRRs within 8 wk of ﬂights of varying duration, i.e., 0–4 h,
4–8 h, 8–12 h, 12–16 h, and longer than 16 h. If time windows
were overlapping, only the duration of the longest ﬂight was
considered for this analysis (Figure 1B). The absolute risk per
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the number of cases that occurred within 8 wk of a ﬂight by
the total number of ﬂights in the corresponding category.
Furthermore, we calculated the increase in risk for each extra
hour of duration of a ﬂight using Poisson regression.
The occurrence of venous thrombosis in relation to the
period of time that had passed after travelling was assessed by
calculating IRs and IRRs for periods of 0–2 wk, 2–4 wk, 4–8
wk, and 8–12 wk after a ﬂight of at least 4 h. The period of 12
wk after a ﬂight was split into these four time windows,
creating mutually exclusive exposure windows. If a person
was exposed to several ﬂights and hence to more than one
time window, the overlapping time was counted only in the
time window closest to the ﬂight (Figure 1C).
Results
A total of 27,496 employees were invited to participate and
8,755 questionnaires were completed, yielding an overall
response of 32% (range per organisation 15%–80%). General
characteristics of the study population are shown in Table 1.
More than half of the responders (n ¼ 4,915, 56%) were men
and the mean age was 40 y. The total follow-up time of
participating employees was 38,910 PY, with a mean follow-
up per participant of 4.4 y.
Flight Data
Flight data are shown in Table 1. The 8,755 responders had
made 315,762 ﬂights during follow-up, and 6,440 individuals
had travelled by air at least once. Approximately one-third of
all ﬂights were long-haul ﬂights (at least 4 h, n¼100,208). The
mean number of long-haul ﬂights per person per year was 2.6
(range 0–48, median 3.5).
Thrombotic Events
In total, 76 employees reported that they had suffered from
venous thrombosis in the follow-up period. Of these 76
possible cases 23 were not validated: four employees did not
give permission for medical chart review, two doctors could
not be traced, six appeared to have suffered from an arterial
event (such as myocardial infarction), and 11 had been
diagnosed with superﬁcial thrombophlebitis. The remaining
53 employees all had an objectively conﬁrmed venous
thrombotic event. Deep vein thrombosis of the leg was
diagnosed in 34, pulmonary embolism in nine, a combination
in eight, and deep vein thrombosis of the arm in two.
Absolute Risks and Incidence Rate Ratios
The overall IR of venous thrombosis was 1.4/1,000 PY (95%
conﬁdence interval [CI] 1.0–1.8/1,000 PY). The total time
employees were exposed to a postﬂight period of 8 wk added
up to 6,872 PY when only ﬂights longer than 4 h were
considered. Within 8 wk of a long-haul ﬂight 22 events
occurred, yielding an IR of 3.2/1,000 PY (95% CI 2.0–4.7/1,000
PY). The time the employees were not exposed to any ﬂight
(long- or short-haul) was 27,772 PY, during which 29 cases
occurred, yielding an IR of 1.0/1,000 PY (95% CI 0.7–1.5/1,000
PY). Thus, the IRR was 3.2 (95% CI 1.8–5.6). The total number
of long-haul ﬂights made by the employees was 102,429,
hence the absolute risk of venous thrombosis was 21.5/100,000
ﬂights, or 1/4,656 ﬂights.
Both the unexposed incidence rate and the incidence rate
in the exposed were higher in women (1.3/1,000 PY and 4.4/
1,000 PY) than in men (0.8/1,000 PY and 2.7/1,000 PY), so their
IRRs were approximately the same (Table 2). Although the IR
of venous thrombosis in the unexposed group increased with
age, in the individuals exposed to air travel it was highest in
the youngest age category (4.9/1,000 PY, 95% CI 0.9–12.1/
Figure 1. Example of the Calculation of Person-Years of Exposure in Three Different Ways
An employee makes one flight of 6 h on day 1 and another flight of 11 h on day 10.
(A) Per number of flights: from day 1 to 10, this employee is exposed to only one flight. Exposure from day 10 to 56, is two flights; from day 56 to 66,
one flight.
(B) Per category of duration: from day 1 to 10 the employee is exposed to one flight of 6 h (so 10 d in the category of 4–8 h); from day 10 to 56, to two
flights, of which the longest is 11 h (so 46 d in the category of 8 12 h); from day 56 to 66, one flight of 11 h (so again 10 d in the category of 8–12 h).
(C) Per time window. From day 1 to 10, the employee is exposed to the time window of 0–2 wk due to the first flight. At day 10, the time is ‘‘reset,’’ so
from day 10 to 24, the employee is exposed to the time window of 0–2 wk again. From day 24 to 38, the employee is exposed to the time window of 2–
4 wk, from day 38 to 66 the time window of 4–8 wk and, finally, from day 66 to 94 the time window of 8–12 wk.
doi:10.1371/journal.pmed.0040290.g001
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Travel and VT: Absolute Risk1,000 PY) and lowest in the oldest (2.9/1,000 PY, 95% CI 0.7–
6.5/1,000 PY), and hence the IRR decreased with age, with an
IRR of 7.7 (95% CI 1.6–38.4) for those under 30 (Table 2).
Women using oral contraceptives had an increased risk of
venous thrombosis, both at baseline (IR 1.9, 95% CI 0.6–3.9)
and after long distance ﬂights (IR 6.6, 95% CI 1.2–16.4). Thus,
the IRR of exposure to air travel was higher in women using
oral contraceptives (3.6, 95% CI 0.8–14.9) than in women not
using oral contraceptives (2.2, 95% CI 0.6–8.1).
The baseline IR of venous thrombosis did not differ much
between subgroups based on height. The IR after air travel
was highest in individuals shorter than 165 cm (IR 6.3/1,000
PY, 95% CI 2.4–12.0/1,000 PY) and lowest in those between
165 and 185 cm (IR 2.4/1,000 PY, 95% CI 1.2–4.0/1,000 PY). In
employees taller than 185 cm, the IR after air travel was 3.6/
1,000 PY (95% CI 0.9–8.1/1,000 PY). Hence, the IRR was
highest in the shortest employees (IRR 9.8, 95% CI 3.1–30.9).
BMI did not affect the baseline thrombosis risk, but the IR
after air travel was higher in employees with a BMI over 25 kg/
m
2 (4.7/1,000 PY, 95% CI 2.6–7.4/1,000 PY) than in those with
a BMI lower than 25 kg/m
2 (1.9/1,000 PY, 95% CI 0.7–3.7/1,000
PY).
The risk of venous thrombosis increased with the number
of ﬂights per employee, as shown in Table 3. When someone
was exposed to only one or two long-haul ﬂights, the IR per
1,000 PY was 2.6 (95% CI 1.4–3.2), which tripled after
exposure to ﬁve or more long-haul ﬂights. With each extra
Table 1. General Characteristics of the Study Population and
Flight Data
Characteristic Subcategory Value
Age, mean (range), y 39.9 (18–71)
Sex, % Males 56
Oral contraceptive use
(% in women ,50)
No OC use entire FU period 56.5
OC use during part of the FU period 26.1
OC use during the complete FU period 17.3
Height, n (%) ,165 cm 2,046 (23.5)
165–180 cm 5,445 (62.6)
.180 cm 1,202 (13.8)
BMI, n (%), kg/m
2 ,25 4,741 (54.7)
.25 3,934 (45.3)
Flights, n Total flights 315,762
Flights 0–4 h 213,333
Flights 4–8 h 46,272
Flights 8–12 h 37,904
Flights 12–16 h 13,208
Flights .16 h, 5,045
Median (range) flights per year 3.5 (0–143)
Median (range) flights .4 h per year 0.8 (0–48)
Flight duration, h Mean (range) duration per flight 3.9 (0–24)
doi:10.1371/journal.pmed.0040290.t001
Table 2. Incidence Rates, Absolute Risks, and Incidence Rate Ratios within 8 Weeks of Long-Haul Flights, for the Whole Study
Population and Stratified by Sex, Age, Oral Contraceptive Use, Height, and BMI
Category Air
Travel
a
Cases Person-Years IR/1,000 PY
(95% CI)
IRR
(95% CI)
b
Flights Risk/Flight
c Case/Number
of Flights
d
All (8,755) No 29 27,772 1.0 (0.7–1.5) Reference
Yes 22 6,872 3.2 (2.0–4.7) 3.2 (1.8–5.6) 102,429 21.5 1/4,656
Men (4,915) No 12 14,728 0.8 (0.4–1.4) Reference
Yes 13 4,810 2.7 (1.4–4.4) 2.7 (1.2–6.0) 76,461 17.0 1/5,882
Women (3,819) No 17 12,968 1.3 (0.8–2.0) Reference
Yes 9 2,050 4.4 (2.0–7.8) 3.3 (1.5–7.5) 25,780 34.9 1/2,864
,30 y (1,392) No 3 4,132 0.7 (0.1–1.8) Reference
Yes 3 616 4.9 (0.9–12.1) 7.7 (1.6–38.4) 8,014 37.4 1/2,671
30–50 y (6,017) No 17 19,576 0.9 (0.5–1.3) Reference
Yes 15 4,879 3.1 (1.7–4.9) 3.7 (1.8–7.5) 73,624 20.4 1/4,908
.50 y (1,345) No 9 4,063 2.2 (1.0–3.9) Reference
Yes 4 1,376 2.9 (0.7–6.5) 1.4 (0.4–4.6) 20,791 19.2 1/5,198
OC
e No No 9 10,193 1.0 (0.5–1.8) Reference
Yes 3 1,533 2.3 (0.4–5.6) 2.2 (0.6–8.1) 18,085 20.3 1/4,938
OC
e Yes No 5 2,367 1.9 (0.6–3.9) Reference
Yes 3 436 6.6 (1.2–16.4) 3.6 (0.8–14.9) 7,695 55.3 1/1,808
,165 cm No 5 7,284 0.7 (0.2–1.5) Reference
Yes 7 1,108 6.3 (2.4–12.0) 9.8 (3.1–30.9) 14,250 49.1 1/2,036
165–185 cm No 21 16,759 1.3 (0.8–1.9) Reference
Yes 11 4,602 2.4 (1.2–4.0) 1.9 (0.9–3.9) 69,095 15.9 1/6,281
.185 cm No 3 3,493 0.9 (0.2–2.1) Reference
Yes 4 1,115 3.6 (0.9–8.1) 3.7 (0.8–16.9) 18,242 21.9 1/4,561
BMI ,25 No 16 14,919 1.1 (0.6–1.7) Reference
Yes 7 3,617 1.9 (0.7–3.7) 1.9 (0.8–4.7) 51,958 13.5 1/7,423
BMI .25 No 13 12,546 1.0 (0.5–1.7) Reference
Yes 15 3,198 4.7 (2.6–7.4) 4.9 (2.3–10.6) 49,509 30.3 1/3,301
aNo,no exposure to air travel within 8 wk; yes, exposure to a flight of at least 4 h.
bIRR adjusted for age and sex.
cRisk per flight: risk per 100,000 flights.
dNumber of flights needed to cause one case.
eOral contraceptive use amongst women ,50 y.
doi:10.1371/journal.pmed.0040290.t002
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Travel and VT: Absolute Riskﬂight the employees were exposed to, the risk increased 1.4-
fold (95% CI 1.2–1.6).
The effect of duration of travel is shown in Table 4. The IR
increased from 0.5/1,000 PY (95% CI 0–1.4/1,000 PY) when
employees had travelled less than 4 h to 5.9/1,000 PY (95% CI
1.5–13.4/1,000 PY) when they had travelled for more than 16
h. For each extra hour of ﬂight duration, the IRR increased
1.1-fold (95% CI 1.1–1.2). Expressed as risk per number of
ﬂights, the risk increased from 1/106,667 ﬂights for ﬂights
shorter than 4 h up to 1/1,264 for ﬂights longer than 16 h.
In Table 5, the IRs and IRRs are shown in relation to the
time that had elapsed after travelling. In the ﬁrst 2 wk after a
long-haul ﬂight, the risk of venous thrombosis was highest,
with an IR per 1,000 PY of 4.7 (95% CI 2.4–7.7). The risk
gradually decreased with time and returned to the baseline
risk after 8 wk.
Discussion
In this follow-up study, we found an overall absolute risk of
symptomatic venous thrombosis of 1/4,656 passengers within
8 wk after ﬂights longer than 4 h. This risk is equivalent to an
IR of 3.2/1,000 PY. The risk was 3.2-fold increased compared
to those who did not travel by air. The risk of venous
thrombosis increased with exposure to several ﬂights and
longer duration of travel, and it decreased with time after a
ﬂight. It was particularly high in younger travellers, women
(especially those taking oral contraceptives), individuals who
were particularly short (,165 cm) or tall (.185 cm), and
those with a BMI over 25 kg/m
2, although due to the small
number of cases, some conﬁdence intervals were wide,
indicating considerable uncertainty for the effect estimates.
The observed rate ratio of 3.2 for ﬂights longer than 4 h is
similar to the odds ratios found in most case-control studies
[3,4,7,8]. Only two studies have previously described absolute
risks of venous thrombosis after air travel, but only for severe
pulmonary embolism occurring immediately after ﬂying
[9,10]. In our study, the risk of venous thrombosis was highest
in the ﬁrst 2 wk after air travel, which was also demonstrated
by Kelman in a record-linkage study [5].
Previous studies showed a dose–response relationship
between the distance travelled and the risk of venous
thrombosis [9,10]. In our study we observed three dose–
response relationships. The risk of venous thrombosis
increased with (1) duration of air travel and (2) number of
ﬂights, and (3) decreased with time after the ﬂight. These
dose–response relationships are in line with a causal
association between air travel and deep vein thrombosis.
The effect of air travel was pronounced in women using
oral contraceptives. This synergy of oral contraceptive use
and air travel was also demonstrated in a previous case-
control study [7]. Travellers who were shorter than 165 cm or
taller than 185 cm also had a higher risk of venous thrombosis
after air travel than those with a height between 165 and 185
cm. In the tall travellers, this may be explained by an
extremely cramped position due to insufﬁcient leg-space. In
travellers who are shorter than 165 cm, the increased risk may
be explained by pressure on the poplitial vein by the airplane
seat, when their feet do not touch the ﬂoor. This higher risk
in both tall and short travellers was previously found in a
large population-based case-control study [3]. This is an
important ﬁnding that has now been demonstrated in two
different populations, indicating a need for adjustable seating
in aircraft.
A remarkable ﬁnding in our study was that the IR of venous
thrombosis after exposure to ﬂights shorter than 4 h seemed
lower (0.5/1,000 PY) than the unexposed IR (1.0/1,000 PY).
Although the conﬁdence intervals were wide and a difference
by chance cannot be ruled out, we think that it may be
explained by a so-called healthy traveller effect, which has
also been proposed by Kelman and colleagues [5]. This
hypothesis proposes that the IR in the absence of travel is
lower in a travelling population than in the general
population because the former is generally healthier. To
Table 3. Incidence Rates and Incidence Rate Ratios for Exposure
to an Increasing Number of Flights
Number
of Flights
Cases Person-Years IR/1,000 PY
(95%CI)
IRR (95%CI)
a
0 29 27,772 1.0 (0.7–1.5) Reference
b
1 or 2 13 5,052 2.6 (1.4–3.2) 2.5 (1.2–4.9)
3 or 4 6 1,494 4.4 (1.5–8.7) 4.2 (1.4–10.3)
5 or more 3 547 7.2 (1.3–18.0) 6.9 (1.3–22.3)
Only flights longer than 4 h were taken into account.
aIRR adjusted for age and sex.
bThe reference category for calculation of incidence rate ratios was no flight longer than 4
h in the preceding 8 wk.
doi:10.1371/journal.pmed.0040290.t003
Table 4. Incidence Rates and Incidence Rate Ratios after Flights of Increasing Duration
Duration Cases Person-Years IR/1,000 PY (95% CI) IRR (95% CI)
a Flights Risk/flight
b Case/number of flight
c
No flight 29 27,772 1.0 (0.7–1.5) 1
d —— —
0–4 hrs 2 4,267 0.5 (0–1.4) 0.4 (0.1–1.9) 213,333 0.9 1/106,667
4–8 hrs 5 2,180 2.3 (0.7–4.8) 2.3 (0.9–5.9) 46,272 10.8 1/9,254
8–12 hrs 6 2,676 2.2 (0.8–4.4) 2.2 (0.9–5.4) 37,903 15.8 1/6,317
12–16 hrs 7 1,344 5.2 (2.0–9.9) 5.3 (2.3–12.4) 13,209 53.0 1/1,887
.16 hrs 4 672 5.9 (1.5–13.4) 5.7 (2.0–16.5) 5,045 79.3 1/1,264
aIRR adjusted for age and sex.
bRisk per flight: risk per 100,000 flights.
cNumber of flights needed to cause one venous thrombosis.
dThe reference category for calculation of incidence rate ratios was no flight in a time-window of 8 wk.
doi:10.1371/journal.pmed.0040290.t004
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Travel and VT: Absolute Riskassess whether this was the case in our study, we separately
calculated the baseline (unexposed) IRs for employees who
travelled at least once a year and for those who travelled less
than once a year. We found that the baseline IR was indeed
lower in employees who travelled more frequently (IRs 0.5/
1,000 PY versus 1.2/1,000 PY for those who travelled less). One
could therefore argue that only employees who made at least
one long-haul ﬂight per year should be used as a reference
group, which would have resulted in higher IRRs (which can
be inferred from the tables). However, the absolute risks
would have remained the same.
Another unexpected ﬁnding in this study was the high risk
in young travellers. This result may be due to a phenomenon
called attrition of susceptibles, meaning that susceptible
individuals are likely to develop a disease shortly after start of
exposure to a risk factor, such as haemorrhage shortly after
start of anticoagulant therapy [18]. Most employees in our
cohort had been frequent travellers long before our
observation period started. The youngest employees are most
likely to be ‘‘new frequent travellers,’’ thus possibly explain-
ing the high absolute risk of thrombosis after air travel in the
youngest age category. We assessed whether this was the case
as follows: If attrition of susceptibles is present, the baseline
IR (i.e., the IR of venous thrombosis without exposure to air
travel) in employees who rarely travel (less than once a year)
would increase with age. The baseline incidence in employees
who ﬂy frequently (more than once a year) would not increase
as much with age, since in this group, susceptible individuals
would already have suffered from venous thrombosis at a
younger age, soon after they became frequent traveller, and
hence been excluded from our study population. We found
that in our study, the baseline IR in individuals with a low
travel-frequency (less than once a year) indeed rose from 0.7/
1,000 PY in the youngest age category (,30 y), to 3.2/1,000 PY
in the oldest age category (.50 y). In contrast, in individuals
with a higher travel frequency, the baseline IR in both the
youngest age category and those between 30 and 50 y was 0.8/
1,000 PY, whereas no venous thrombosis occurred in 1,521 PY
in the oldest age category. Furthermore, in the individuals
with a low travel frequency (less than once per year), the
incidences in all age groups were very high when they did
travel (24/1,000 PY for those under 30 y, 7/1,000 PY for those
between 30 and 50 y, and 40/1,000 PY for those over 50 y). So,
in these individuals who do not travel on a regular basis, the
thrombosis risk is high when they occasionally do. These
results all suggest that the risk of air-travel related venous
thrombosis is highest in susceptible persons soon after they
ﬁrst start travelling by air, i.e., that attrition of susceptibles is
present.
A possible limitation of this study is the response of 32%.
Employees who had suffered from venous thrombosis may be
more likely to complete the questionnaire than employees
who had not. These factors would create bias only if
employees who suffered from venous thrombosis directly
after air travel responded more frequently than those who
suffered from thrombosis without air travel. The response
varied considerably per organisation between 15% and 80%.
To assess the effect of the response, we analyzed organisations
with a low response ( 60%) and those with a high response
(.60%) separately. The outcomes did not differ substantially
between these two groups of employees, indicating that the
low response did not bias our ﬁndings. Furthermore, we may
have missed employees who died or stopped working due to
disability resulting from a venous thrombosis. Although these
events are unlikely to have occurred often, it may have led to
an underestimation of the number of cases.
Another limitation is that these results cannot be gener-
alized to an older, less-healthy population. This study was
performed in a working population with a mean age of 40 y.
We do not have any data on people older than age 70 y, nor
on individuals who are not ﬁt enough to be employed.
Considering these limitations, the absolute risk of venous
thrombosis in the general population is likely to be higher
than the risk we found. Furthermore, the results cannot be
generalized to individuals that have a history of venous
thrombosis, as we considered only ﬁrst events.
From this cohort study among employees of international
organisations and companies, we conclude that the absolute
risk of symptomatic venous thrombosis within 8 wk of a ﬂight
of at least 4 h is approximately 1/4,500 ﬂights. Furthermore,
we found three dose–response relationships: the risk of
venous thrombosis increased with duration of travel and
number of ﬂights a person was exposed to and decreased with
time after a long-haul ﬂight. The results of our study do not
justify the use of potentially dangerous prophylaxis such as
anticoagulant therapy for all long-haul air travellers, since
this may do more harm than good [17]. However, for some
subgroups of people with a highly increased risk, the risk–
beneﬁt ratio may favour the use of prophylactic measures.
Large randomized trials are required to assess who would
beneﬁt most from which prophylactic measure.
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Editors’ Summary
Background. Blood normally flows smoothly throughout the human
body, supplying the brain and other vital organs with oxygen and
nutrients. When an injury occurs, proteins called clotting factors make
the blood gel or coagulate at the injury site. The resultant blood clot
(thrombus) plugs the wound and prevents blood loss. Sometimes,
however, a thrombus forms inside an uninjured blood vessel and partly
or completely blocks the blood flow. A clot inside one of the veins
(vessels that take blood to the heart) deep within the body is called a
deep vein thrombosis (DVT). Symptoms of DVT (which usually occurs in
the deep veins of the leg) include pain, swelling, and redness in one leg.
DVT is usually treated with heparin and warfarin, two anticoagulant
drugs that stop the blood clot growing. If left untreated, part of the clot
(an embolus) can break off and travel to the lungs, where it can cause a
life-threatening condition called pulmonary embolism (PE). Fortunately,
DVT and PE are rare but having an inherited blood clotting disorder,
taking an oral contraceptive, and some types of surgery are all risk
factors for them. In addition, long-haul plane travel increases the risk of
DVT and PE, known collectively as venous thrombosis (VT) 2- to 4-fold, in
part because the enforced immobilization during flights slows down
blood flow.
Why Was This Study Done? Although the link between air travel and VT
was first noticed in the 1950s, exactly how many people will develop DVT
and PE (the absolute risk of developing VT) after a long flight remains
unknown. This information is needed so that travelers can be given
advice about their actual risk and can make informed decisions about
trying to reduce that risk by, for example, taking small doses of
anticoagulant medicine before a flight. In this study, the researchers have
determined the absolute risk of VT during and after long-haul air travel in
a large group of business travelers.
What Did the Researchers Do and Find? The researchers enrolled
almost 9,000 employees from several international companies and
organizations and followed them for an average of 4.4 years. The details
of flights taken by each employee were obtained from company records,
and employees completed a Web-based questionnaire about whether they
had developed VT and what risk factors they had for the condition. Out of
53 thrombi that occurred during the study, 22 occurred within eight weeks
of a long-haul flight (a flight of more than four hours). From this and data
on the total time employees spent on long-haul flights, the researchers
calculated that these flights tripled the risk of developing VT, and that the
absolute risk (the probability of something occurring in a certain time
period) of a VT occurring shortly after such travel was one event per 4,656
flights. They also calculated that the risk of VT was increased by exposure to
more flights during a short period and to longer flights and was greatest in
the first two weeks after a flight. In addition, the risk of VT was particularly
high in young employees, women taking oral contraceptives, and people
who were short, tall or overweight.
What Do These Findings Mean? The main finding of this study is that
the absolute risk of VT after of a long-haul flight is low—only one
passenger out of nearly 5,000 is likely to develop VT because of flying.
However, the study included only healthy people without previous VT
whose average age was 40 years, so the absolute risk of VT after long-
haul flights might be higher in the general traveling population. Even so,
this finding strongly suggests that prophylactic (preventative) use of
anticoagulants by all long-haul travelers may not be justified because
these drugs have potentially dangerous side effects (for example, they
can cause uncontrolled bleeding). Subgroups of travelers with additional
risk factors for VT might, however, benefit from the use of this and other
prophylactic measures, but randomized trials are needed to find out who
would benefit most from which prophylactic measure.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040290.
  MedlinePlus encyclopedia pages on blood clots, deep vein
thrombosis, and pulmonary embolism (in English and Spanish)
  Information from the US National Heart Lung and Blood Institute on
deep vein thrombosis, including an animation of how DVT causes
pulmonary embolisms
  Information for patients from the UK National Health Service Direct
health encyclopedia on deep vein thrombosis (in several languages)
  Information for travelers on DVT from the US Centers for Disease
Control and Prevention and from the UK National Travel Health
Network and Centre
  This study came out of the WHO Research Into Global Hazards of
Travel (WRIGHT) project, and WHO’s WRIGHT project on Air Travel and
Venous Thromboembolism, of which his study forms a part, has a Web
site
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